PAR-2 antagonist inhibits bleomycin-induced lung fibrosis. Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019
Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice Source: Eur Respir J 2008; 32: 426-436 Year: 2008
SD-208 an orally active TGF-β1 receptor antagonist inhibits TGF-β1 induced progressive lung fibrosis in rat Source: Annual Congress 2003 - Animal models of lung injury: useful or not? Year: 2003
Inhibitory effect of PGE2 receptor subtype, EP4, in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2007 - Mechanisms of injury and repair in fibrotic, idiopathic or infectious lung disease Year: 2007
The effects of AMD3100, a CXCR4 antagonist, on the bleomycin-induced pulmonary fibrosis Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009
Endothelin-1 receptor antagonist prevents hyperoxia-induced parenchymal mechanical impairment in mice Source: Eur Respir J 2004; 24: Suppl. 48, 334s Year: 2004
Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice Source: Eur Respir J 2005; 25: 708-714 Year: 2005
Inhibition of the Arp2/3 complex inhibits lung myofibroblast differentiation in vitro and attenuates bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019
Simultaneous inhibition of CTGF and Autotaxin reduces lung fibrosis and improves lung function in mice Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021
A role of prostaglandin D2 receptor, CRTH2, on bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Understanding allergic airway inflammation with the help of animal models Year: 2008
Abrogation of bleomycin induced inflammation and lung fibrosis by angiotensin AT1 receptor antagonist. Relevance of PGE-2 modulation Source: Eur Respir J 2005; 26: Suppl. 49, 82s Year: 2005
The treatment of bleomycin-induced lung injury with combination of antioxidants and interleukin-1 receptor antagonist (IL-1ra) Source: Eur Respir J 2002; 20: Suppl. 38, 488s Year: 2002
Metformin attenuates bleomycin-induced pulmonary fibrosis in mice via IGF-1 suppression Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias Year: 2018
Blockage of serotonin receptors and transporter reduces bleomycin lung fibrosis in mice Source: Eur Respir J 2005; 26: Suppl. 49, 82s Year: 2005
An orally available, highly selective 5-hydroxytryptamine 2B (5-HT2B) receptor antagonist ameliorating pulmonary and dermal fibrosis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019
Anti-fibrotic effect of telmisartan on bleomycin-induced lung fibrosis in mice Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008
PD98059 attenuates the development of bleomycin-induced lung injury and fibrosis Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010
Anti-fibrotic effects of liver X receptor agonists in human fetal lung fibroblasts Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011
Selective endothelin-A receptor blockade attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013
Protease-activated receptor-4 deficiency does not protect against bleomycin-induced pulmonary fibrosis in mice}, Source: Eur Respir J 2012; 40: 1056-1057 Year: 2012